By Colin Kellaher

 

Agenus Inc. (AGEN) on Thursday said the U.S. Food and Drug Administration accepted the company's investigational new drug application for AGEN2373, triggering a $7.5 million milestone payment from Gilead Sciences Inc. (GILD).

The Lexington, Mass., clinical-stage immuno-oncology company in December formed a partnership with Gilead to develop and commercialize up to five novel immuno-oncology therapies.

Under the deal, Agenus received $150 million upfront from Gilead and is eligible for roughly $1.7 billion in future fees and milestones.

"AGEN2373 has unique binding properties and is designed to mitigate the toxicity observed with competitor molecules," Agenus said. "We believe that this molecule has great potential for patients with cancer."

Shares of Agenus rose 3.2% in premarket trading Thursday.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

August 08, 2019 09:08 ET (13:08 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Gilead Sciences Charts.